Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC
Launched by EASTERN HEPATOBILIARY SURGERY HOSPITAL · Feb 8, 2017
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II), also known as des-γ-carboxyprothrombin (DCP) or acarboxy prothrombin, is an abnormal form of prothrombin induced by vitamin K absence or antagonist-II. The study is intended to evaluate the diagnostic efficiency of Protein Induced by Vitamin K Absence or antagonist-II(PIVKA-II). PIVKA-II as an effective tumor marker for hepatocellular carcinoma(HCC) has been widely used in the western countries where most cases ar...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 85
- • Receiving no treatment before diagnosis
- • Establishing Diagnosis according to the Asian Pacific Association for the Study of Liver(APASL) criteria
- Exclusion Criteria:
- • Clinical data missing
- • Laboratory tests information missing
- • Serum samples doesn't qualified
- • Obstructive jaundice patients
- • Medical history of taking warfarin
About Eastern Hepatobiliary Surgery Hospital
Eastern Hepatobiliary Surgery Hospital is a premier medical institution specializing in hepatobiliary and pancreatic surgeries, renowned for its cutting-edge research and clinical excellence. With a commitment to advancing patient care through innovative surgical techniques and comprehensive research initiatives, the hospital plays a pivotal role in the development and execution of clinical trials aimed at improving outcomes for patients with liver, gallbladder, and pancreatic conditions. Its multidisciplinary team of experts collaborates to ensure rigorous adherence to ethical standards and protocols, fostering a research environment that prioritizes patient safety and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials